Bioassay of estrogenic compounds in transgenic Arabidopsis plants carrying a recombinant human estrogen receptor gene and a GFP reporter gene.

Transgenic Res

Research Center for Environmental Genomics, Kobe University, Rokkodaicho 1-1, Nada-ku, Kobe, Hyogo 657-8501, Japan.

Published: December 2009

AI Article Synopsis

  • Transgenic Arabidopsis plants were engineered to include a human estrogen receptor gene and a green fluorescent protein for detecting estrogenic compounds.
  • Multiple variations of the human estrogen receptor genes were created, with the XEV design showing the highest sensitivity, detecting as little as 0.001 ng/ml of estradiol.
  • These plants absorbed certain estrogenic compounds from the nutrient solution, with successful detection of various chemicals like estrone and bisphenol A through PCR techniques, indicating their potential use in bioassaying estrogenic substances.

Article Abstract

Transgenic Arabidopsis plants carrying a recombinant human estrogen receptor gene and a green fluorescent protein reporter gene were used to bioassay estrogenic compounds. We constructed four recombinant human estrogen receptor genes by combining the DNA-binding domain of LexA, a synthetic nuclear localization signal, a ligand-binding domain of the human estrogen receptor, and a transactivation domain of VP16 in different orders; the XEV plants were the most sensitive, and were able to detect 0.001 ng ml(-1) of 17ss-estradiol (E(2)). The transgenic plants absorbed E(2) and 4-nonylphenol present in the nutrient solution, whereas most of the other compounds seemed to be retained in, or on, the roots. Estrone, methoxychlor, bisphenol A, 4-nonylphenol, and 4-t-octylphenol in the medium were clearly detected by RT-PCR and PCR of the genomic DNA. The transgenic Arabidopsis XEV plants thus have potential for the bioassay of estrogenic compounds.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11248-009-9277-9DOI Listing

Publication Analysis

Top Keywords

human estrogen
16
estrogen receptor
16
bioassay estrogenic
12
estrogenic compounds
12
transgenic arabidopsis
12
recombinant human
12
arabidopsis plants
8
plants carrying
8
carrying recombinant
8
receptor gene
8

Similar Publications

New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor-Positive Breast Cancer.

Annu Rev Med

January 2025

Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus and Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; email:

Oral selective estrogen receptor degraders (SERDs) are pure estrogen receptor antagonists that have the potential to overcome common resistance mechanisms to endocrine therapy in estrogen receptor-positive breast cancer. There are currently five oral SERDs in published and ongoing clinical trials-elacestrant, camizestrant, giredestrant, imlunestrant, and amcenestrant-with more in development. They offer a reasonably well-tolerated oral therapy option with low discontinuation rates in studies.

View Article and Find Full Text PDF

Objective: Breast cancer stands as the most prevalent form of cancer among women globally. This heterogeneous disease exhibits varying clinical behaviors. The stratification of breast cancer patients into risk groups, determined by their metastasis and survival outcomes, is pivotal for tailoring personalized treatments and therapeutic interventions.

View Article and Find Full Text PDF

Triple-negative breast cancer (TNBC) is a unique breast cancer subtype characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression in tumor cells. TNBC represents about 15% to 20% of all breast cancers and is aggressive and highly malignant. Currently, TNBC diagnosis primarily depends on pathological examination, while treatment efficacy is assessed through imaging, biomarker detection, pathological evaluation, and clinical symptom improvement.

View Article and Find Full Text PDF

Designing and validating an adaptation tool for endometriosis: an exploratory mixed method study protocol.

Reprod Health

January 2025

Reproductive Health, Nursing and Midwifery Care Research Center, Midwifery Group, Mashhad University of Medical Sciences, Mashhad, Iran.

Background: Endometriosis is a benign and chronic gynecological estrogen-dependent condition. Research findings have highlighted its impact on different aspects of women's lives. Enhancing quality of life and supporting the well-being of those affected is advised.

View Article and Find Full Text PDF

Endogenous sex hormone levels are associated with the revised Framingham Stroke Risk Profile in postmenopausal women: a longitudinal study in a Swedish cohort.

BMC Endocr Disord

January 2025

Family medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Box 454, Göteborg, 40530, Sweden.

Background: Endogenous sex hormones in postmenopausal women have been associated with risk of cardiovascular diseases. The aim of this study was to determine the association between endogenous sex hormones and the revised Framingham Stroke Risk Profile (rFSRP) in postmenopausal women.

Methods: This is an observational cross-sectional study on the Vara-Skövde cohort, a Swedish population-based study for longitudinal surveillance of the development and progress of type 2 diabetes and hypertension.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!